Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

407 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
[Compensation of occupational diseases during monitoring of the ARDCO cohort].
Gislard A, Gramond C, Clin B, Paris C, Delva F, Brochard P, Laurent F, Benoist J, Andujar P, Chouaïd C, Thaon I, Boudet L, Pairon JC. Gislard A, et al. Among authors: chouaid c. Rev Mal Respir. 2024 Sep;41(7):472-487. doi: 10.1016/j.rmr.2024.06.010. Epub 2024 Jul 25. Rev Mal Respir. 2024. PMID: 39060158 French.
Association between lung cancer somatic mutations and occupational exposure in never-smokers.
Paris C, Do P, Mastroianni B, Dixmier A, Dumont P, Pichon E, Chouaid C, Coudert B, Foucher P, Fraboulet S, Locatelli-Sanchez M, Baize N, Dansin E, Moreau L, Vincent M, Missy P, Morin F, Moro-Sibilot D, Couraud S; BioCAST/IFCT-1002 study investigators; to the BioCAST/IFCT- 1002 study. Paris C, et al. Among authors: chouaid c. Eur Respir J. 2017 Oct 26;50(4):1700716. doi: 10.1183/13993003.00716-2017. Print 2017 Oct. Eur Respir J. 2017. PMID: 29074543 Free article.
Lung cancer, comorbidities, and medication: the infernal trio.
Pluchart H, Chanoine S, Moro-Sibilot D, Chouaid C, Frey G, Villa J, Degano B, Giaj Levra M, Bedouch P, Toffart AC. Pluchart H, et al. Among authors: chouaid c. Front Pharmacol. 2024 Feb 21;14:1016976. doi: 10.3389/fphar.2023.1016976. eCollection 2023. Front Pharmacol. 2024. PMID: 38450055 Free PMC article. Review.
Nivolumab plus ipilimumab versus carboplatin-based doublet as first-line treatment for patients with advanced non-small-cell lung cancer aged ≥70 years or with an ECOG performance status of 2 (GFPC 08-2015 ENERGY): a randomised, open-label, phase 3 study.
Léna H, Greillier L, Cropet C, Bylicki O, Monnet I, Audigier-Valette C, Falchero L, Vergnenègre A, Demontrond P, Geier M, Guisier F, Hominal S, Locher C, Corre R, Chouaid C, Ricordel C; GFPC 08–2015 ENERGY investigators. Léna H, et al. Among authors: chouaid c. Lancet Respir Med. 2024 Oct 29:S2213-2600(24)00264-9. doi: 10.1016/S2213-2600(24)00264-9. Online ahead of print. Lancet Respir Med. 2024. PMID: 39486424
Double immune checkpoint inhibitor therapy for unresectable pleural mesothelioma rarely induces hyperprogressive disease: a case report.
Naulleau G, Monnet I, Rousseau-Bussac G, Vinas F, Mangiapan G, Jabot L, Boudjemaa A, Chouaïd C, Auliac JB, Assié JB. Naulleau G, et al. Among authors: chouaid c. Transl Lung Cancer Res. 2024 Sep 30;13(9):2448-2452. doi: 10.21037/tlcr-24-382. Epub 2024 Sep 6. Transl Lung Cancer Res. 2024. PMID: 39430317 Free PMC article.
407 results